Home » Subgroup Analysis Suggests Benefit From Afatinib in Some Lung Cancer Patients
Subgroup Analysis Suggests Benefit From Afatinib in Some Lung Cancer Patients
New data … show that afatinib leads to a significant four-fold extension (4.4 months vs. 1 month for placebo) in progression-free survival — the time before a tumour starts to grow again — for lung cancer patients most likely to have an epidermal growth factor receptor (EGFR) mutation.
iStockAnalyst
iStockAnalyst
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May